These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Aug 29, 2017
Pfenex Inc. (NYSE MKT: PFNX) announced today that it will be presenting at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12th, 2017 at 10:50 am ET. The conference...
-
Aug 23, 2017
Pfenex Inc. (NYSE MKT: PFNX) announced today that it will be presenting at the 6th Annual Liolios Gateway Conference on September 6th, 2017 at 11:00 am PT. The conference will be held at the Four...
Aug 9, 2017Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
-
Aug 3, 2017
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
-
Jul 25, 2017
Pfenex Inc. (NYSE MKT: PFNX) announced today that its second quarter 2017 financial results will be released on Wednesday August 9, 2017, after the market close. At 4:30 pm Eastern Time, Pfenex...
-
Jun 8, 2017
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
May 8, 2017Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
-
Apr 24, 2017
Pfenex Inc. (NYSE MKT: PFNX) announced today that its first quarter 2017 financial results will be released on Monday, May 8, 2017, after the market close. At 4:30 pm Eastern Time, Pfenex...
Apr 3, 2017Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
- Mar 31, 2017
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...